The [Arg8]vasopressin (AVP) receptor expressed by human hepatocytes was characterized, and compared with the rat hepatic Vl vasopressin receptor subtype. In addition to determining the pharmacological profile of the human receptor, the cellular responses to AVP were measured in human and rat hepatocytes by assaying glycogen phosphorylase a activity and DNA synthesis. Marked differences were observed between human and rat hepatocytes regarding vasopressin receptors and the intracellular consequences of stimulation by AVP. Data presented in this paper demonstrate the following. (i) Vasopressin Vl receptors are present in low abundance on human hepatocytes. (ii) Species differences exist between human and rat Vla receptors with respect to the affinity of some selective antagonists. (iii) AVP-stimulated glycogen phosphorylase a activation in human hepatocytes was approx. 5 % of that observed in rat cells. (iv) In contrast with rat hepatocytes, DNA synthesis in human cells in culture was not stimulated by AVP. It is concluded that vasopressin plays only a minor role in the regulation of human hepatic function. Furthermore, conclusions drawn from observations made with AVP and its analogues on rat hepatic function cannot be directly extrapolated to the human situation.
INTRODUCTION
The neurohypophysial hormone [Arg8]vasopressin (AVP) has a variety of physiological effects, including well-characterized pressor and antidiuretic activities (reviewed by Jard, 1983) . In common with many other hormones and neurotransmitters, AVP exerts its actions through more than one type of receptor. Michell et al. (1979) classified these vasopressin receptor subtypes according to the effector system to which they are coupled: V1 receptors stimulate phosphoinositidase C to generate the second messengers Ins(1,4,5)P3 and diacylglycerol (Berridge & Irvine, 1984) , whereas V2 receptors stimulate adenylate cyclase. V1 receptors are expressed in vascular smooth muscle, where they mediate the vasopressor response, and V2 receptors are located in the renal tubule, where they regulate antidiuresis (Michell et al., 1979) . More recently, inconsistencies in the pharmacological profile of V1 receptors in vascular smooth muscle and the anterior pituitary gland (Knepel et al., 1983; Antoni, 1984; Baertschi & Friedli, 1985; Raymond et al., 1985) have resulted in a further sub-classification of these receptors into Vla (smooth muscle) and Vlb (anterior pituitary) .
The vasopressin receptor expressed by mammalian hepatocytes is the Vla subtype, as indicated by its pharmacological characteristics Keppens & DeWulf, 1979; Cantau et al., 1980) and by the effector system to which it couples (Kirk & Hems, 1974; Keppens et al., 1977; Kirk et al., 1981) . AVP occupancy of these receptors rapidly initiates glycogenolysis (Hems & Witton, 1973 by stimulating the conversion of glycogen phosphorylase b to glycogen phosphorylase a (Keppens & DeWulf, 1975; Cantau et al., 1980) . In addition, prolonged exposure to AVP in vivo enhanced the rate of liver regeneration in the genetically AVP-deficient Brattleboro rat following partial hepatectomy (Russell & Bucher, 1983a) and potentiated DNA synthesis in primary cultures of normal rat hepatocytes (Russell & Bucher, 1983b) . These studies of the characteristics of the Via receptor expressed in liver, and of the physiological role of AVP in hepatic function, have predominantly utilized rodents as the tissue source. Observations made using rodent liver are then often extrapolated to other mammals, including man. Access to normal healthy human liver has enabled us to study the Vla receptor of human liver directly.
In this paper, the Vla receptor expressed by human hepatocytes is compared with the rat liver vasopressin receptor by investigating three different parameters of hepatic vasopressin receptor function. The receptor protein is studied directly in liver cell membranes using radioligand-binding techniques. The shortterm and long-term physiological consequences of agonist activation of this receptor in hepatocytes (i.e. glycogenolysis and DNA synthesis) are appraised by assaying the activity of glycogen phosphorylase a and the incorporation of [3H]thymidine into DNA respectively. Our data indicate that profound differences exist between the human and rat liver Vla receptors with respect to all three parameters studied, thereby making extrapolation from rat liver to human liver invalid with regard to AVP function.
MATERIALS AND METHODS
[Phe-3,4,5-3H]AVP (67.7 Ci/mmol), the labelled Via-selective vasopressin antagonist 4, Jard et al., 1986;  see the legend to Table 1 for definition of abbreviations) and the selective oxytocin (OT) agonist [Thr4,Gly7]OT (Lowbridge et al., 1977) were obtained from Bachem. The V2-selective vasopressin antagonist [d(CH2)5-D-Ile2,Ile4]AVP (Manning et al., 1984) Adenylate cyclase assay Adenylate cyclase activity in human liver samples was measured using a protocol identical to that described by Keen et al. (1989) , based on the method of Sharma et al. (1975) (1981) , except that the initial perfusion medium was a Ca2 -, Mg2+-free Krebs-Ringer bicarbonate buffer with Hepes (120 mM-NaCl, 4.7 mM-KCI, 11.5 mM-glucose, 25 mM-NaHCO3 and 10 mM-Hepes, pH 7.4). The yield of rat hepatocytes was (2-3) x 107 cells/g wet wt.
Human hepatocytes were prepared from an unused portion of donor liver. A wedge (100-200 g) of human liver with one cut surface was cannulated with two 16G venflons. Perfusion details were similar to those described for the rat (see above), except that the Ca2+-free perfusion medium was supplemented with EGTA (0.5 mM) and the enzyme mixture contained collagenase (0.5 mg/ml), dispase (1 mg/ml), deoxyribonuclease (0.05 mg/ml) and hyaluronidase (0.5 mg/ml). After about 30 min of enzyme recirculation (50 ml/min), and once softening of the liver was observed, perfusion was terminated and the liver was minced and agitated to disaggregate the cells. Cells were isolated and washed three times by centrifugation (50 g, 2 min) and resuspension in perfusion buffer supplemented with 10% (v/v) fetal calf serum. The yield of human hepatocytes from one liver portion prepared in this manner was in the range (2-5) x 106 cells/g wet wt.
The viability of all hepatocyte preparations was assessed by the Trypan Blue exclusion method and was 90-95 % for rat hepatocytes and 75-95 % for human hepatocytes. The metabolic integrity of the hepatocyte preparations was established by assaying the ATP content of the cells using a bioluminescent assay kit (Sigma) according to the manufacturers' instructions. The ATP content of rat and human hepatocytes was 5.5 + 0.4 (n = 5) and 6.2 + 1.0 (n = 3) pg/cell respectively, 24 h after the initiation of culture. This is comparable with the 7.5 pg/cell previously reported for viable rat hepatocytes (Baur et al., 1975) . These values did not vary significantly from the time of hepatocyte production to the end of the experiment. The measured ATP content corresponds to a tissue concentration of 2.4-2.7 /smol/g of tissue, which is similar to that reported in vivo and for perfused liver (Hems et al., 1966) . The metabolic integrity of the hepatocytes was corroborated by the observation that the hepatocytes' DNA repair mechanisms were intact (Dr. J. K. Chipman, personal communication) and that the cells were responsive to hepatocyte growth factor (Strain et al., 1991) . Stimulation and assay of glycogen phosphorylase a activity
The protocol used for hormonal stimulation of glycogen phosphorylase (EC 2.4.1.1) was based upon the method of Kirk Characteization of the human liver vasopressin receptor et al. (1979) . Briefly, freshly prepared hepatocytes -were transferred to perfusion medium supplemented with 1.8 mM-CaCl2, 1.2 mM-MgCl2 and BSA (2 mg/ml), and 450 ,ul portions (approx. 5 x 106 cells/ml) were preincubated for 30 min at 37 'C. Hormones were then added to the cell suspension and the medium was briefly flushed with 02/CO2 (19:1) before incubation at 37 'C in a shaking water bath (80-90 cycles/min). Incubations were terminated after 2 min by rapidly pipetting 400 ,l# of cell suspension into sample tubes precooled in liquid N2. Samples were stored at -75 'C before assay. After adding to the frozen sample 400 ,ul of an ice-cold medium containing 100 mmglycylglycine and 200 mM-NaF, pH 7.4, the hepatocytes were homogenized at 0 'C using 20 strokes of a Teflon/glass homogenizer. Entry of the fluorescent dye Procion Yellow MX-4R into cells validated the effectiveness of this homogenization protocol.
Glycogen phosphorylase a activity was assayed by measuring the incorporation of radioactive glucose from ['4C]glucose 1-phosphate into glycogen at 30 'C (Hems et al., 1976) . A 50,ul portion of homogenate was added to 50 ,1 of an assay medium containing 30 mM-[14C]glucose 1-phosphate, 20 mg of glycogen/ml (pretreated with Amberlite MB-1), 200 mM-KF, 20 mM-EDTA, 1 mM-caffeine and 66 mM-Mes, pH 6.3, at 30 'C.
After 20 min, the reaction was stopped by the addition of 400 #1 of ice-cold 6o% (w/v) trichloroacetic acid containing glycogen
(1 mg/ml) and LiBr (2 mg/ml). Glycogen was precipitated by ethanol (800,1), pelleted (10000 g, 30 s) and washed twice by resuspension in water and ethanol precipitation. The washed glycogen pellet was resuspended in water and incorporated radioactivity was determined by liquid scintillation spectroscopy.
Maintenance of hepatocyte cultures
Hepatocytes were plated on to rat-tail-collagen-coated Petri dishes (Strain et al., 1982) at a density 3 x 105 cells/dish (Falcon; 35 mm) in a volume of 2 ml (Dulbecco's minimal essential medium + 10 % fetal calf serum). Following attachment (30 min for rat, 2 h for human), cells were washed twice in phosphatebuffered saline (PBS; ICN-Flow Laboratories) and maintained in 1.5 ml of culture medium (modified arginine-free Williams' E medium; Imperial Laboratories) supplemented with 2 mM-Lglutamine, 0.4 mM-ornithine, 5.5 juM-cortisol, 100 units of penicillin/ml, 100,ug of streptomycin/ml and 0.1 ,uM-insulin at 37°C in a C02/air (1:19) the specific binding of [3H]AVP in each human sample was saturable and was to a single class of site ( Fig. 1) with a Kd of 0.59 + 0.04 nm (mean+S.E.M., n = 3). This is comparable with the affinity of the rat liver receptor (KdO.68 + 0.14 nM; mean + S.E.M., n = 5). Calculation of the number of AVP-binding sites expressed by human liver membranes revealed a capacity (BmaX.) ranging from 7.9 fmol/mg of membrane protein to a maximum of 102.8 fmol/mg ofmembrane protein, with a mean (± S.E.M.) of 52.2+9.0 fmol/mg of protein (n = 10). This value is very much lower than that of 326.7+17.5 fmol/mg of membrane protein (n = 5) observed in rat liver membranes prepared by the same method. Stimulation of glycogen phosphorylase a in hepatocytes Fig. 3 presents the dose-response curves of AVP-stimulated glycogen phosphorylase a activity in rat and human hepatocytes. AVP increased glycogen phosphorylase a activity in rat hepatocytes in a dose-dependent manner from a basal level of 0.19 + 0.07 ,umol/min per 0I cells (mean+ S.E.M., n = 5). Maximal stimulation was produced by 1 nM-AVP, which increased phosphorylase a activity by 680 + 101 % (n = 5) over basal, with an EC50 (concn. producing 50 % activation) of 54 pM (Fig. 3) . A concentration of AVP (562 pM) which ordinarily stimulated a near-maximal phosphorylase a activity was without effect when (1986, 1988) , except where indicated: *data from this laboratory. glucagon. Glycogen phosphorylase a activity was increased by 298 + 38 % (n = 3) over basal after stimulation by 10 nMglucagon. In control experiments, rat hepatocytes were prepared using the method employed for the production of human hepatocytes (see the Materials and methods section). A membrane preparation from these cells exhibited the same ligandbinding characteristics as membranes prepared from rat hepatocytes generated by the routine protocol. Furthermore, these hepatocytes displayed the same dose-response curve as the routinely produced rat hepatocytes with respect to AVPstimulated glycogen phosphorylase a activity (results not shown).
Effect of AVP on DNA synthesis in primary hepatocyte cultures Comparison of control rat and human hepatocyte cultures showed that mean basal levels of [3H]thymidine incorporation into DNA in rat hepatocytes was 6.3-fold higher than in human hepatocytes (Table 3) . AVP treatment of rat hepatocyte cultures increased DNA synthesis in a dose-dependent manner, with a saturating concentration of AVP (100 nM) increasing
[3H]thymidine incorporation into DNA by 1.8-fold. Furthermore, the Via-selective antagonist [d(CH2)5-Tyr(Me)2]AVP completely inhibited the AVP-induced increase in DNA synthesis in rat hepatocyte cultures, showing that this response to AVP was mediated by agonist occupancy of the hepatic V16 receptor. In contrast, even a saturating concentration of AVP had no effect upon DNA synthesis in human hepatocyte cultures. EGF was a potent stimulant of DNA synthesis in both rat and human hepatocyte cultures. Incubation with EGF (0.85 nM) increased the incorporation of [3H]thymidine into DNA by 6.1-fold and 5.9-fold in rat and human hepatocyte cultures respectively (Table  3) .
DISCUSSION
We have studied the hitherto poorly characterized vasopressin receptor expressed by human liver and compared its characteristics to those of the well-defined Vla vasopressin receptor subtype expressed by rat liver. The receptors were investigated at three different levels of receptor function: (1) the interaction of ligands with the receptor and its coupled second messenger system, (2) the short-term (minutes) AVP-induced stimulation of glycogen phosphorylase a activity, and (3) the long-term (days) AVP-induced increase in DNA synthesis.
[3H]AVP-binding sites were detected on human liver membranes (Fig. 1) . Binding to these sites was specific, saturable Vol. 276 and displayed an affinity for AVP typical of that exhibited by vasopressin receptors in the rat (Table 1) (Michell et al., 1979) , hence the lack of adenylate cyclase responsiveness to AVP would preclude classifying the human liver receptor as V2.
Third, activation of the receptors stimulated inositol pfpl te production. Consequently, both rat and human express the Via receptor. The differences in the a [d(CH2)5-D-Ile2,jle4]AVP for the Via receptors of rat and hunp liver probably reflect a genuine species difference. Such species differences have been noticed by others when studying vasopressin antagonists in the rat and dog (Liard et al., 1982; Stassen et al., 1983 Assay of glycogen phosphorylase a activity was chosen as a monitor of short-term activation ofhepatic vasopressin receptors, as it has been very well-characterized in the rat by many groups. The dose-response curve for AVP-stimulated phosphorylase activity in the rat (Fig. 3) was typical, as previously reported by others (e.g. Hems et al., 1976) . The curve obtained using human hepatocytes was similar to this with respect to the EC50, and in that 1 nM-AVP caused maximum phosphorylase activation. However, the degree to which AVP modulated phosphorylase a activity differed markedly between rat and human hepatocytes, with the mean maximum activation in the human only approx. 5 % of that in the rat (Fig. 3) . This small response in human hepatocytes was not due to an impaired metabolic state, as assessed by the ATP content. Furthermore, glucagon stimulated an increase in phosphorylase a activity similar to that reported by others (Pieniazek et al., 1986) . In addition, the reduced stimulation of glycogen phosphorylase by AVP in human cells was not due to a lack of the intracellular signalling mechanism, as both AVP and phenylephrine stimulated inositol phosphate production (Table 2) . Although the extent of inositol phosphate accumulation in human cells was less than that reported for the rat (Palmer et al., 1986) , it was very similar to that reported by Thakker et al. (1989) for AVP-stimulation of human hepatocytes. Thakker et al. (1989) also found that PtdInsP2 hydrolysis in human hepatocytes was similar in magnitude when mediated by either AVP receptors or a1-adrenergic receptors; this too is in agreement with our observations. The AVP-stimulated glycogen phosphorylase activation in the rat exhibits a receptor reserve, with the apparent EC50 for the response being 12-fold lower than the binding constant (Kd) of the agonist. This is still apparent in the human, but only a 2.5-fold difference was observed, probably reflecting the reduced number of receptors expressed by human hepatocytes. These data would imply that the role of AVP in the regulation of liver glycogen metabolism in humans is minor compared with the situation in the rat. Although the reason for this difference and its physiological ramifications are not clear, it is not a unique circumstance. Vandekerckhove et al. (1989) recently reported that the glycogen phosphorylase a of rabbit hepatocytes was not modulated by AVP. In addition, the ob/ob mouse hepatocyte does not express vasopressin receptors, unlike the corresponding lean controls (Assimacopoulos-Jeannet et al., 1983) .
The suggestion that AVP has only a minor role in regulating human hepatic function is supported by the data on DNA synthesis. AVP has been reported to promote growth of several cell types in culture, including hepatocytes (Russell & Bucher, 1983a,b; Hunt et al., 1977; Miller et al., 1977) , and this was confirmed for rat hepatocytes (Table 3) . However, although exposure of human hepatocyte cultures to EGF resulted in a pronounced stimulation of DNA synthesis, AVP was without effect.
The data presented in this paper characterize the human liver vasopressin receptor and demonstrate that marked differences exist between the rat and the human with respect to regulation of liver function by AVP. Consequently, conclusions drawn from data obtained using AVP and its analogues in rat liver cannot merely be extrapolated to the human liver.
